Medication info
Aromil Tablets (Glymepiride)

Aromil Tablets (Glymepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Ajou Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200400686 · Notified 2004.02.24 · Insurance code 654000730

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 glass of water. Administer this drug orally once daily. This drug should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received drug therapy, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 to 2 weeks. In general, doses greater than 4 mg provide little additional benefit, but some patients have achieved better metabolic control with dose increases up to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this drug needed may decrease. Therefore, dose reduction or discontinuation of this drug may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral glucose-lowering drug to this drug There is no exact dose equivalence between this drug and other oral glucose-lowering drugs. When switching from another oral glucose-lowering drug to this drug, it is advisable to follow the instructions given under Initial dose. That is, treatment may be initiated at 1 mg once daily, with dose adjustment at 1- to 2-week intervals. The potency and duration of action of the previously administered drug should be taken into account. 4) Dose adjustment during treatment While taking this drug, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after successful initial management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate treatment and follow-up by a physician and may sometimes require hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary treatment failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this drug once daily with the first meal, and initiate insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to identify the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this drug is administered concomitantly with metformin, and the risk may increase. Appropriate caution should be exercised.

Ingredients

Manufacturer
Ajou Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. It can be administered alone or in combination with insulin or other oral hypoglycemic agents, along with dietary and exercise regimens. Particularly in cases where blood sugar control is difficult with sulfonylureas or monotherapy with metformin, using this medication in combination with metformin enhances effectiveness. This treatment approach helps maintain stable blood sugar levels and aids in managing diabetes. Therefore, this medication is very effective in improving blood sugar control.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 glass of water. Administer this drug orally once daily. This drug should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received drug therapy, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 to 2 weeks. In general, doses greater than 4 mg provide little additional benefit, but some patients have achieved better metabolic control with dose increases up to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this drug needed may decrease. Therefore, dose reduction or discontinuation of this drug may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral glucose-lowering drug to this drug There is no exact dose equivalence between this drug and other oral glucose-lowering drugs. When switching from another oral glucose-lowering drug to this drug, it is advisable to follow the instructions given under Initial dose. That is, treatment may be initiated at 1 mg once daily, with dose adjustment at 1- to 2-week intervals. The potency and duration of action of the previously administered drug should be taken into account. 4) Dose adjustment during treatment While taking this drug, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after successful initial management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate treatment and follow-up by a physician and may sometimes require hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary treatment failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this drug once daily with the first meal, and initiate insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to identify the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this drug is administered concomitantly with metformin, and the risk may increase. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent type 1 diabetes or those in diabetic ketoacidosis or coma. It should also not be administered in cases of allergic reactions to this medication or sulfonylureas and sulfonamides. There is no experience in using this medication in patients with severe liver or kidney dysfunction, and in such cases, switching to insulin therapy is recommended. This medication should not be used in pregnant women, women who may become pregnant, or nursing mothers. Patients with severe infections, before and after surgery, or with severe trauma may require insulin treatment. Patients experiencing gastrointestinal disturbances such as diarrhea or vomiting may have an increased risk of hypoglycemia due to improper absorption of food, so caution is advised. During the first week of taking this medication, there is a higher risk of hypoglycemia, so blood sugar levels should be monitored frequently and carefully observed. Particularly cautious measures are necessary for the elderly, patients with poor nutritional status or irregular eating patterns, and those who consume insufficient carbohydrates after intense exercise or experience changes in meal patterns. Patients frequently consuming alcohol or with impaired kidney or liver function may also have increased risk for hypoglycemia. Additionally, caution is needed for patients who overdose on this medication or have thyroid, pituitary, or adrenal dysfunction. If taking other medications, interactions that could affect blood sugar control should be discussed with a doctor. This medication has the effect of lowering blood sugar, and hypoglycemia may occur, with symptoms such as headache, severe hunger, nausea, fatigue, anxiety, confusion, dizziness, drowsiness, and loss of consciousness. Severe hypoglycemia can lead to seizures or coma, so immediate intake of sugar or medical assistance should be sought if symptoms appear. Initial doses may also produce blurred vision or gastrointestinal symptoms (nausea, vomiting, abdominal pain). Serious side effects such as liver dysfunction or decreased blood cell counts may occur rarely, and any unusual symptoms should be reported to a doctor immediately. Allergic reactions such as hives, rash, and difficulty breathing may occur, so immediate discontinuation of the medication and consultation with medical personnel should be sought if such symptoms arise. While taking this medication, it is important to maintain a regular diet, exercise, and weight management, and to periodically check blood sugar control status. In cases of hypoglycemia, rapid intake of sugar is the most effective, and it is advisable to always carry sugar. Patients and families should be adequately educated about hypoglycemia symptoms and risk factors. In stress situations or during surgery, infections, or when blood sugar control becomes difficult, temporary switching to insulin therapy may be necessary. During treatment, regular checks of blood sugar and urinalysis should be conducted to assess the medication's effect and adjust treatment as necessary. This medication may interact with other drugs, so it is essential to inform healthcare providers about new medications being taken or discontinued. In particular, there may be fluctuations in blood sugar control when taken with drugs that affect the enzymes that metabolize this medication in the liver. It is important to inform the doctor of all medications currently being taken that may raise or lower blood sugar. It is safer not to use this medication in pregnant or nursing women, and switching to insulin therapy is recommended if necessary. In children under 18, this medication's safety and efficacy have not been established, so it is best not to use it. Elderly patients may have decreased kidney function, necessitating dosage adjustments for this medication. In cases of overdose, severe hypoglycemia may occur, requiring immediate hospital care and possible treatments such as inducing vomiting, gastric lavage, or glucose injection. This medication should be stored out of reach of children, sealed in its original container.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbances, anxiety, aggression, decreased concentration, diminished agility or drive, depression, confusion, speech abnormalities, aphasia, visual impairment, tremors, incomplete paralysis, sensory disturbances, dizziness, weakness, loss of self-control, temporary mental confusion, cerebral convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina pectoris, deep vein thrombosis, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased hepatic enzymes, liver dysfunction, biliary secretion disorder, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis, pancytopenia, itching, urticaria, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, photosensitivity reactions of the skin, decreased serum sodium concentration, taste disturbances, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, dyspepsia, facial swelling, impotence, facial flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. A storage temperature of 1 to 30 degrees Celsius at room temperature is recommended. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.